cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Incyte Corporation
18 own
13 watching
Current Price
$62.11
$-0.58
(-0.93%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
11,878.29M
52-Week High
52-Week High
67.36000
52-Week Low
52-Week Low
50.27000
Average Volume
Average Volume
3.45M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
36.3859
iconMarket Capitalization11,878.29M
icon52-Week High67.36000
icon52-Week Low50.27000
iconAverage Volume3.45M
iconDividend Yield--
iconP/E Ratio36.3859
What does the Incyte Corporation do?
Incyte Corporation focuses on the discovery, development, and commercialization of proprietary therapeutics in oncology in the United States and internationally. It offers JAKAFI for the treatment of myelofibrosis and polycythemia vera cancers. The company's clinical stage products include ruxolitinib cream that is in Phase II clinical trial for the treatment of alopecia areata and atopic dermatitis; and baricitinib, which is in Phase III clinical trial for treatment of rheumatoid arthritis. In addition, it is developing itacitinib that is in Phase I/II clinical trials in combination with osimertinib for non-small cell lung cancer (NSCLC); INCB52793, INCB54329 (BRD), INCB57643 (BRD), and INCB53914 (PIM), which are in Phase I/II trials for the treatment of advanced malignancies; INCB54828 (FGFR1/2/3) that is in Phase II clinical trial the treatment of bladder cancer, cholangiocarcinoma, and 8p11 MPNs; INCB59872 (LSD1), which is in Phase II clinical trial the treatment of acute myeloid leukemia and small cell lung cancer; and capmatinib that is in Phase II clinical trial for the treatment of NSCLC and liver cancer. Further, the company's clinical stage products include epacadostat, which is in Phase II clinical trial for the treatment of various tumors, and in Phase I/II clinical trials for the treatment of NSCLC and bladder cancer, as well as in Phase III clinical trial for the treatment of advanced melanoma; and INCB01158, INCSHR1210, INCAGN1876 (GITR), and INCAGN1949 (OX40), which are in Phase I/II clinical trials for the treatment of solid tumors. It markets its JAKAFI product through a network of specialty pharmacy providers and wholesalers. The company has collaboration agreements with Novartis International Pharmaceutical Ltd.; Eli Lilly and Company; Agenus Inc.; Jiangsu Hengrui Medicine Co., Ltd.; Merus N.V.; Calithera Biosciences, Inc; Pfizer Inc; and Abramson Cancer Center. Incyte Corporation was founded in 1991 and is headquartered in Wilmington, Delaware.
Read More
How much money does Incyte Corporation make?
News & Events about Incyte Corporation.
Globe Newswire
1 year ago
NEW YORK, April 24, 2023 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Incyte Corporation (Incyte or the Company) (NASDAQ:INCY). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980. The investigation ...
Business Wire
1 year ago
Incyte (Nasdaq:INCY) today announced that the European Commission (EC) has granted a marketing authorization for Opzelura (ruxolitinib) cream 15mg/g for the treatment of non-segmental vitiligo with facial involvement in adults and adolescents from 12 years of age. Opzelura is the first and only...
Globe Newswire
1 year ago
NEW YORK, April 09, 2023 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Incyte Corporation (Incyte or the Company) (NASDAQ:INCY). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980. The investigation ...
Business Wire
1 year ago
Incyte (Nasdaq:INCY) today announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) has approved Pemazyre (pemigatinib), a selective fibroblast growth factor receptor (FGFR) inhibitor, for the treatment of myeloid/lymphoid neoplasms (MLNs) with FGFR1 fusion (also known as 8p11...
Business Wire
1 year ago
Incyte (Nasdaq:INCY) today announced that the U.S. Food and Drug Administration (FDA) has issued a complete response letter for ruxolitinib extended-release (XR) tablets, a JAK1/JAK2 inhibitor, for once-daily (QD) use in the treatment of certain types of myelofibrosis (MF), polycythemia vera (PV...
Frequently Asked Questions
Frequently Asked Questions
What is Incyte Corporation share price today?
plus_minus_icon
Can Indians buy Incyte Corporation shares?
plus_minus_icon
How can I buy Incyte Corporation shares from India?
plus_minus_icon
Can Fractional shares of Incyte Corporation be purchased?
plus_minus_icon
What are the documents required to start investing in Incyte Corporation stocks?
plus_minus_icon
What is today’s traded volume of Incyte Corporation?
plus_minus_icon
What is today’s market capitalisation of Incyte Corporation?
plus_minus_icon
What is the 52-Week High and Low Range of Incyte Corporation?
plus_minus_icon
What percentage is Incyte Corporation down from its 52-Week High?
plus_minus_icon
What percentage is Incyte Corporation up from its 52-Week Low?
plus_minus_icon
Current Price
$62.11
$-0.58
(-0.93%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Get Started with as little as $1.00